Related Experiment Video
Updated: Jun 6, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with
S Ramachandran1, S Saraf, C Shetty
1Department of Clinical Biochemistry, Good Hope Hospital, Heart of England Foundation Trust, Sutton Coldfield, West Midlands, UK. sud.ramachandran@heartofengland.nhs.uk
Annals of Clinical Biochemistry
|December 1, 2010
Summary
Certain statins, like simvastatin and atorvastatin, may paradoxically decrease HDL-cholesterol (HDL-C) in some patients. This rare effect was observed in a type 2 diabetes patient, unlike with pravastatin or rosuvastatin.
Area of Science:
- Cardiovascular Pharmacology
- Lipid Metabolism Disorders
Background:
- Statins are primary agents for lowering LDL-cholesterol (LDL-C) in cardiovascular disease prevention.
- Statins typically increase HDL-cholesterol (HDL-C) moderately; paradoxical HDL-C decreases are rare and previously undocumented with statins alone.
Observation:
- A patient with type 2 diabetes experienced a significant, paradoxical decrease in HDL-C and apolipoprotein A1 levels.
- This effect occurred specifically with simvastatin and atorvastatin, but not with pravastatin or rosuvastatin therapy.
Findings:
- The observed HDL-C reduction was linked to specific statin treatments, not statin-fibrate combinations.
- Simvastatin and atorvastatin, which share lipophilic properties, induced the paradoxical HDL-C fall, while hydrophilic statins did not.
Implications:
- This case highlights a potential, rare adverse effect of certain statins on HDL-C levels.
- Further research is needed to elucidate the mechanisms behind statin-induced paradoxical HDL-C decrease and identify at-risk patients.
More Related Videos
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...